[CAMBRIDGE, USA – May 13^th 2025] – The animal CRISPR therapeutics industry is achieving unprecedented clinical success, according to a new 310-page ClearView Market Insights report. The market is expected to grow at a CAGR of 32.1%, reaching $9.8 billion by 2031, thus redefining veterinary care.

Request Sample @ https://clearviewmarketinsights.com/report-details/animal-crispr-therapeutics

Key Industry Shifts

1. Disease Eradication

• Feline PKD Cure:
• Stops cyst growth in 94% of treated cats
• Canine DMD Therapy:
• Restores 80% muscle function

2. Regulatory Milestones

• FDA Fast Track:
• 6-month review pathway established
• USDA Exemption:
• Single-base edits not classified as GMO

3. Economic Transformation

• Breeder Adoption:
• 40% of Persian cat breeders use PKD editing
• Insurance Coverage:
• Nationwide covers 50% of therapy cost

Executive Insights

• Dr. Jennifer Doudna, CRISPR Tx Advisor:
  "We're curing diseases before birth in animals - human medicine is next."
• Daniel Oliver, Rejuvenate CEO:
  "One treatment replaces a lifetime of expensive care."

Future Projections

• 2027: First FDA approval for canine DMD
• 2029: Germline editing becomes routine
• 2031: 30% of purebreds genetically optimized

For more insights, visit https://clearviewmarketinsights.com/report-store

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369